Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 6;7(3):171-177.
doi: 10.1016/j.ncrna.2022.07.001. eCollection 2022 Sep.

MicroRNAs as prognostic markers and therapeutic targets in gliomas

Albert Sufianov  1   2   3 , Sema Begliarzade  4 , Tatiana Ilyasova  5 , Yanchao Liang  6   7 , Ozal Beylerli  3
Affiliations
Review

MicroRNAs as prognostic markers and therapeutic targets in gliomas

Albert Sufianov et al. Noncoding RNA Res. .

Abstract

Gliomas are invasive brain tumors characterized by high rates of recurrence and mortality. Glioblastoma (GBM), a grade IV brain tumor, is known for its heterogenicity and its resistance to the current treatment regimen. MicroRNA (miRNAs) are small non-coding sequences of RNA that regulate and influence the expression of multiple genes. The detection of certain types of micro-RNA in tissues and blood serum can be used for diagnosis and prognosis, including the response of a particular patient to therapy. The purpose of this review is to analyze studies and experimental results concerning changes in microRNA expression profiles characteristic of gliomas. Furthermore, miRNAs also contribute to autophagy at multiple stages. In this review, we summarize the functions of miRNAs in GBM pathways linked to dysregulation of cell cycle control, apoptosis and resistance to treatment, and the possible use of miRNAs in clinical settings as treatment and prediction biomarkers.

Keywords: Brain tumors; Gliomas; Molecular markers; Therapeutic targets; microRNAs.

PubMed Disclaimer

Conflict of interest statement

The authors declare that no conflicts of interest exist.

Figures

Fig. 1
Fig. 1
Potential miRNAs that can be used as prognostic markers and therapeutic targets in gliomas.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. International Agency for Research on Cancer (IARC) GLOBOCAN 2008. Estimated incidence, mortality and 5-year prevalence: both sexes. http://globocan.iarc.fr Available online:
    1. Mamelak A.N., Jacoby D.B. Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601) Expet Opin. Drug Deliv. 2007;4(2):175–186. doi: 10.1517/17425247.4.2.175. - DOI - PubMed
    1. Louis D.N., Ohgaki H., Wiestler O.D., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109. doi: 10.1007/s00401-007-0243-4. - DOI - PMC - PubMed
    1. Li M., Li J., Liu L., et al. MicroRNA in human glioma. Cancers. 2013;5(4):1306–1331. doi: 10.3390/cancers5041306. - DOI - PMC - PubMed
    1. Hayes J., Thygesen H., Tumilson C., et al. Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature. Mol. Oncol. 2015;9(3):704–714. doi: 10.1016/j.molonc.2014.11.004. - DOI - PMC - PubMed

LinkOut - more resources